Design, synthesis and biological evaluation of nonpeptide integrin antagonists.

Abstract

Recent studies demonstrated that peptide and antibody antagonists of integrin alpha v beta 3 block angiogenesis and tumor growth. In this article, the design, synthesis and biological evaluation of a series of nitroaryl ether-based, nonpeptide mimetics are described. The design of these compounds was based on Merck's arylether/alpha-aminoacid/guanidine framework and incorporates a novel nitroaryl system. The synthesized mimetics were tested against a variety of integrins (alpha v beta 3, alpha IIb beta 3, and alpha v beta 5) in order to determine their binding selectivity and ability to inhibit cell adhesion. Selected compounds were also tested for their ability to inhibit angiogenesis in vivo in the CAM (chick chorioallantoic membrane) assay. From the generated compound library, compounds 16 and 19 proved to be potent and selective inhibitors of alpha IIb beta 3 (IC50 = 14 nM) whereas compound 11 showed excellent in vivo inhibition of angiogenesis (at 30 micrograms/embryo).

Statistics

050100150'03'05'07'09'11'13'15'17
Citations per Year

107 Citations

Semantic Scholar estimates that this publication has 107 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Nicolaou1998DesignSA, title={Design, synthesis and biological evaluation of nonpeptide integrin antagonists.}, author={K C Nicolaou and J. Trujillo and Bernd Jandeleit and Kelly Chibale and Margaret Rosenfeld and Beate Diefenbach and David A . Cheresh and Simon L. Goodman}, journal={Bioorganic & medicinal chemistry}, year={1998}, volume={6 8}, pages={1185-208} }